Acadia says Alzheimer's psychosis drug clears mid-stage study Reuters Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study, sending its shares up as much as 18.5 percent. The company said the drug, pimavanserin, showed ... |